[Hemodynamic effects of intravenous XXXX in the acute phase of @entity583 ].

@entity1 @entity713 @entity10719 @entity1188 @entity583
The haemodynamic tolerance of intravenous @entity10719 was evaluated during the acute phase of @entity583 . This is a beta-blocker with an intrinsic beta-stimulant effect. The study consisted of 14 @entity1 (10 cases of inferior @entity1188 and 4 cases of anterior @entity1188 ) with a mean capillary pressure of less than 20 mmHg and a cardiac index greater than 2 l X min-1 X m-2. The minimal dose of @entity10719 was 0.05 mg X kg-1 X h-1 and the maximal dose was 0.125 mg X kg-1 X h-1. The intravenous infusion of @entity10719 was commenced between 3 and 12 hours (average: 7.5 hours) after the @entity1188 and was continued for 48 hours, at which time it was replaced by oral administration. The mean total intravenous dose was 409 mg (from 190 to 510 mg). Two @entity1 were excluded from the protocol because of the development of 2nd degree @entity713 several minutes after the beginning of the infusion. The basal values of the cardiac index (2.7 l X min-1 X m-2 +/- 0.37), the mean capillary pressure (9.4 mmHg +/- 2.7) and the systolic index (38.3 ml/m2 +/- 6.4) did not change significantly during the infusion, in the 14 @entity1 studied. The double product, heart rate x blood pressure, decreased from the mean basal value of 9,443 to 7,680 at 24 hours and to 7,000 at 48 hours (p less than 0.05). @entity10719 does not depress left ventricular function, provided that it is reserved for @entity1 with class I or II disease according to Killip and Kimball's classification.(ABSTRACT TRUNCATED AT 250 WORDS)
